Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Catalyst Grant: Cannabis Research in Urgent Priority Areas

University of Calgary

$120,800.00

Cannabinoid Hyperemesis Syndrome: Evaluation of Health Burden and Treatment Strategies

FY 2018-19

Summary
Cannabis is widely used in Canada, with 12% of the population having reported consuming it for medical or recreational purposes in 2015. With long-term daily users, a syndrome characterized by recurring episodes of vomiting and abdominal pain has been identified called cannabinoid hyperemesis syndrome (CHS). Patients with CHS often have a major burden of illness due to repeated emergency room visits, and reduced functioning and quality of life in the community. The reason why CHS occurs is unknown, however, changes in the way the cannabinoid receptors on nerves work in chronic users may play a role. Abstinence from cannabis has been reported to improve CHS symptoms, but even that is not well understood in terms of duration of abstinence. Psychiatric comorbidity may play a role as well. Very little is known about CHS, but is commonly seen in gastroenterology (GI) and emergency departments in recent years, and the incidence appears to be on the rise. Our goal is to study CHS in a systematic way, which has not been done before. First, we will study the demographics, cannabis-use patterns, psychiatric, and social aspects of CHS patients using validated surveys. Patients will be followed prospectively with detailed surveys to better understand the GI symptoms and psychological effects of either continuing or stopping cannabis. For those unable to stop cannabis and who continue to have symptoms, we plan a small prospective clinical trial with haloperidol, an anti-psychotic drug, which may improve symptoms. When Colorado legalized recreational cannabis, the number of emergency department visits for vomiting nearly doubled. With the expected increase in cannabis use in Canada moving forward, the incidence CHS will likely also rise. We feel it is imperative that we study this emerging signal of negative sequelae of chronic cannabis use which is both poorly understood and a major health burden.
Program
Catalyst Grant: Cannabis Research in Urgent Priority Areas
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
392203
Name
Andrews Christopher N
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Clinical
Prcname2
Cannabis Research in Urgent Priority Areas
Projecttitle
Cannabinoid Hyperemesis Syndrome: Evaluation of Health Burden and Treatment Strategies
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$120,800
Cihrequipment2
$0
Programname2
Catalyst Grant: Cannabis Research in Urgent Priority Areas
Keyworddelim
Cannabinoid Hyperemesis Syndrome; Cannabis; Haloperidol; Harm Reduction; Nausea
Abstract
Cannabis is widely used in Canada, with 12% of the population having reported consuming it for medical or recreational purposes in 2015. With long-term daily users, a syndrome characterized by recurring episodes of vomiting and abdominal pain has been identified called cannabinoid hyperemesis syndrome (CHS). Patients with CHS often have a major burden of illness due to repeated emergency room visits, and reduced functioning and quality of life in the community. The reason why CHS occurs is unknown, however, changes in the way the cannabinoid receptors on nerves work in chronic users may play a role. Abstinence from cannabis has been reported to improve CHS symptoms, but even that is not well understood in terms of duration of abstinence. Psychiatric comorbidity may play a role as well. Very little is known about CHS, but is commonly seen in gastroenterology (GI) and emergency departments in recent years, and the incidence appears to be on the rise. Our goal is to study CHS in a systematic way, which has not been done before. First, we will study the demographics, cannabis-use patterns, psychiatric, and social aspects of CHS patients using validated surveys. Patients will be followed prospectively with detailed surveys to better understand the GI symptoms and psychological effects of either continuing or stopping cannabis. For those unable to stop cannabis and who continue to have symptoms, we plan a small prospective clinical trial with haloperidol, an anti-psychotic drug, which may improve symptoms. When Colorado legalized recreational cannabis, the number of emergency department visits for vomiting nearly doubled. With the expected increase in cannabis use in Canada moving forward, the incidence CHS will likely also rise. We feel it is imperative that we study this emerging signal of negative sequelae of chronic cannabis use which is both poorly understood and a major health burden.
Competitiondate
201810
Approvedterm2
1 yr 0 mth
Pinamesdelim
Andrews, Christopher N
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Neurosc Mental Hlth &A~ $120,800~ $0~
University of Calgary - $120,800 Grant (2018-19) | Canada Spends